uremia |
Disease ID | 724 |
---|---|
Disease | uremia |
Manually Symptom | (Waiting for update.) |
Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:19) C0022658 | renal disease | 6 C0004153 | atherosclerosis | 4 C0031046 | pericarditis | 2 C0002871 | anemia | 2 C0021051 | immunodeficiency | 2 C0021311 | infections | 2 C0022661 | end-stage renal disease | 2 C0034063 | pulmonary edema | 1 C0040053 | thrombosis | 1 C0878544 | cardiomyopathy | 1 C0442874 | neuropathy | 1 C0427008 | stiffness | 1 C0033774 | pruritus | 1 C0033845 | pseudotumor cerebri | 1 C0020538 | hypertension | 1 C0162429 | malnutrition | 1 C0003123 | anorexia | 1 C0020502 | hyperparathyroidism | 1 C1393529 | vascular complications | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
---|
(Waiting for update.) |
All Snps(Total Genotypes:2) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
rs1800625 | 20185929 | 5891 | MOK | umls:C0041948 | GAD | [In summary, our study shows for the first time a link between RAGE and GLO polymorphisms in the prognosis of HD patients.] | 0.002367032 | 2010 | AGER;PBX2 | 6 | 32184665 | A | G |
rs4746 | 20185929 | 2739 | GLO1 | umls:C0041948 | GAD | [In summary, our study shows for the first time a link between RAGE and GLO polymorphisms in the prognosis of HD patients.] | 0.002367032 | 2010 | GLO1 | 6 | 38682852 | T | G |
GWASdb Annotation(Total Genotypes:0) | |
---|---|
(Waiting for update.) |
GWASdb Snp Trait(Total Genotypes:0) | |
---|---|
(Waiting for update.) |
Mapped by lexical matching(Total Items:0) |
---|
(Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
---|
(Waiting for update.) |
Chemical(Total Drugs:14) | |||||||||
---|---|---|---|---|---|---|---|---|---|
CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
C0041948 | benazepril | C044946 | 86541-75-5 | uremia | MESH:D014511 | therapeutic | 9725782 | ||
C0041948 | carmustine | D002330 | 154-93-8 | uremia | MESH:D014511 | marker/mechanism | 11219485 | ||
C0041948 | cyclophosphamide | D003520 | 50-18-0 | uremia | MESH:D014511 | marker/mechanism | 582354 | ||
C0041948 | cisplatin | D002945 | 15663-27-1 | uremia | MESH:D014511 | marker/mechanism | 12806945 | ||
C0041948 | calcitriol | D002117 | 32222-06-3 | uremia | MESH:D014511 | therapeutic | 17444814 | ||
C0041948 | enalapril | D004656 | 75847-73-3 | uremia | MESH:D014511 | therapeutic | 17513326 | ||
C0041948 | folic acid | D005492 | 59-30-3 | uremia | MESH:D014511 | marker/mechanism | 4082191 | ||
C0041948 | gemcitabine | C056507 | 103882-84-4 | uremia | MESH:D014511 | marker/mechanism | 11219485 | ||
C0041948 | indomethacin | D007213 | 53-86-1 | uremia | MESH:D014511 | marker/mechanism | 311647 | ||
C0041948 | norepinephrine | D009638 | 51-41-2 | uremia | MESH:D014511 | marker/mechanism | 6652879 | ||
C0041948 | ramipril | D017257 | 87333-19-5 | uremia | MESH:D014511 | therapeutic | 12631109 | ||
C0041948 | rifampin | D012293 | 13292-46-1 | uremia | MESH:D014511 | marker/mechanism | 129898 | ||
C0041948 | streptozocin | D013311 | 18883-66-4 | uremia | MESH:D014511 | marker/mechanism | 11219485 | ||
C0041948 | vincristine | D014750 | - | uremia | MESH:D014511 | marker/mechanism | 582354 |
FDA approved drug and dosage information(Total Drugs:1) | ||||||||
---|---|---|---|---|---|---|---|---|
DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
MESH:D014511 | calcijex | calcitriol | 0.001MG/ML Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | INJECTABLE;INJECTION | Discontinued | None | Yes | No |
FDA labeling changes(Total Drugs:1) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
MESH:D014511 | 11/16/2001 | calcijex | calcitriol | Management of hypocalcemia in patients undergoing chronic renal dialysis | The safety and effectiveness of calcitriol was examined in a double-blind placebo-controlled trial of 35 pediatric patients (13-18 years of age) with end-stage renal disease and on dialysis. The primary efficacy endpoint favored the calcitriol-treated versus the placebo-treated patients Transient hypercalcemia was seen in 1 of 16 calcitriol-treated patients; 6 of 16 (38%) calcitriol-treated patients and 2 of 19 (11%) placebo-treated patients had Ca x P >75 | Labeling | B | - | - | - | Abbott | 02/16/2001 | FALSE' |